Color vision in Parkinson's disease and essential tremor

European Journal of Neurology

Volumn 18, Issue 4, 2011, Pages 577-583

  Oh, Y S ^a   Kim, J S ^a   Chung, S W ^a   Song, I U ^a   Kim, Y D ^a   Kim, Y I ^a   Lee, K S ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Color vision; Essential tremor; Farnsworth Munsell 100 Hue test; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL ASSESSMENT; COLOR DISCRIMINATION; COLOR VISION DEFECT; COLOR VISION TEST; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ESSENTIAL TREMOR; FARNSWORTH MUNSELL 100 HUE TEST; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; PARKINSON DISEASE; PRIORITY JOURNAL;

AGED; CASE-CONTROL STUDIES; COLOR VISION DEFECTS; ESSENTIAL TREMOR; FEMALE; HUMANS; MALE; PARKINSON DISEASE;

EID: 79952731516     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2010.03206.x     Document Type: Article

References (51)

1. Benito-Leon J, Louis ED. Clinical update: diagnosis and treatment of essential tremor. Lancet 2007; 369: 1152-1154.
2. Louis ED. Essential tremor. Lancet Neurol 2005; 4: 100-110.
3. Lim ES, Seo MW, Woo SR, Jeong SY, Jeong SK. Relationship between essential tremor and cerebellar dysfunction according to age. J Clin Neurol 2005; 1: 76-80.
4. Kim JS, Song IU, Shim YS, et al. Cognitive impairment in essential tremor without dementia. J Clin Neurol 2009; 5: 81-84.
5. Ziemssen T, Reichmann H. Non-motor dysfunction in Parkinson's disease. Parkinsonism Relat Disord 2007; 13: 323-332.
6. Chaudhuri KR, Martinez-Martin P. Quantitation of non-motor symptoms in Parkinson's disease. Eur J Neurol 2008; 15: S2-S7.
7. Reijnders JS, Ehrt U, Lousberg R, Aarsland D, Leentjens AF. The association between motor subtypes and psychopathology in Parkinson's disease. Parkinsonism Relat Disord 2009; 15: 379-382.
8. Ondo WG, Lai D. Olfaction testing in patients with tremor-dominant Parkinson's disease: is this a distinct condition? Mov Disord 2005; 20: 471-475.
9. Postuma RB, Gagnon JF, Vendette M, Charland K, Montplaisir J. REM sleep behaviour disorder in Parkinson's disease is associated with specific motor features. J Neurol Neurosurg Psychiatry 2008; 79: 1117-1121.
10. Kim JS, Lee KS, Song IU, et al. Cardiac sympathetic denervation is correlated with Parkinsonian midline motor symptoms. J Neurol Sci 2008; 270: 122-126.
11. Deuschl G, Bain P, Brin M. Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee. Mov Disord 1998; 13: S2-S23.
12. Bodis-Wollner I. Retinopathy in Parkinson disease. J Neural Transm 2009; 116: 1493-1501.
13. Haug BA, Trenkwalder C, Arden GB, Oertel WH, Paulus W. Visual thresholds to low-contrast pattern displacement, color contrast, and luminance contrast stimuli in Parkinson's disease. Mov Disord 1994; 9: 563-570.
14. Bodis-Wollner I, Tagliati M. The visual system in Parkinson's disease. Adv Neurol 1993; 60: 390-394.
15. Haug BA, Kolle RU, Trenkwalder C, Oertel WH, Paulus W. Predominant affection of the blue cone pathway in Parkinson's disease. Brain 1995; 118: 771-778.
16. Harnois C, Di Paolo T. Decreased dopamine in the retinas of patients with Parkinson's disease. Invest Ophthalmol Vis Sci 1990; 31: 2473-2475.
17. Kinnear PR. Proposals for scoring and assessing the 100-Hue test. Vision Res 1970; 10: 423-433.
18. Pieri V, Diederich NJ, Raman R, Goetz CG. Decreased color discrimination and contrast sensitivity in Parkinson's disease. J Neurol Sci 2000; 172: 7-11.
19. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 745-752.
20. Jankovic J. Essential tremor: clinical characteristics. Neurology 2000; 54: S21-S25.
21. Lee JY, Jeon BS, Paek SH, Lim YH, Kim MR, Kim C. Reprogramming guided by the fused images of MRI and CT in subthalamic nucleus stimulation in Parkinson disease. Clin Neurol Neurosurg 2010; 112: 47-53.
22. Kim JW, Cheon SM, Park MJ, Kim SY, Jo HY. Cognitive impairment in Parkinson's disease without dementia: subtypes and influences of age. J Clin Neurol 2009; 5: 133-138.
23. Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 1990; 40: 1529-1534.
24. Stochl J, Boomsma A, Ruzicka E, Brozova H, Blahus P. On the structure of motor symptoms of Parkinson's disease. Mov Disord 2008; 23: 1307-1312.
25. Giladi N, McDermott MP, Fahn S, et al. Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology 2001; 56: 1712-1721.
26. Müller T, Woitalla D, Peters S, Kohla K, Przuntek H. Progress of visual dysfunction in Parkinson's disease. Acta Neurol Scand 2002; 105: 256-260.
27. Diederich NJ, Raman R, Leurgans S, Goetz CG. Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Arch Neurol 2002; 59: 1249-1252.
28. Büttner T, Kuhn W, Müller T, Patzold T, Heidbrink K, Przuntek H. Distorted color discrimination in 'de novo' parkinsonian patients. Neurology 1995; 45: 386-387.
29. Müller T, Meisel M, Russ H, Przuntek H. Motor impairment influences Farnsworth-Munsell 100 Hue test error scores in Parkinson's disease patients. J Neurol Sci 2003; 213: 61-65.
30. Müller T, Kuhn W, Büttner T, Przuntek H. Colour vision abnormalities and movement time in Parkinson's disease. Eur J Neurol 1999; 6: 711-715.
31. Veselá O, Růzicka E, Jech R, et al. Colour discrimination impairment is not a reliable early marker of Parkinson's disease. J Neurol 2001; 248: 975-978.
32. Müller T, Kuhn W, Büttner T, et al. Colour vision abnormalities do not correlate with dopaminergic nigrostriatal degeneration in Parkinson's disease. J Neurol 1998; 245: 659-664.
33. Postuma RB, Gagnon JF, Vendette M, Charland K, Montplaisir J. Manifestations of Parkinson disease differ in association with REM sleep behavior disorder. Mov Disord 2008; 23: 1665-1672.
34. Archibald NK, Clarke MP, Mosimann UP, Burn DJ. The retina in Parkinson's disease. Brain 2009; 132: 1128-1145.
35. Braak H, Braak E, Yilmazer D, Schultz C, de Vos RA, Jansen EN. Nigral and extranigral pathology in Parkinson's disease. J Neural Transm 1995; 46: S15-S32.
36. Masson G, Mestre D, Blin O. Dopaminergic modulation of visual sensitivity in man. Fundam Clin Pharmacol 1993; 7: 449-463.
37. Teuber HL, Proctor F. Some effects of basal ganglia lesions in subhuman primates and man. Neuropsychologia 1964; 2: 85-93.
38. Braak H, Braak E, Yilmazer D, de Vos RA, Jansen EN, Bohl J. New aspects of pathology in Parkinson's disease with concomitant incipient Alzheimer's disease. J Neural Transm 1996; 48: S1-S6.
39. Azulay JP, Mesure S, Amblard B, Blin O, Sangla I, Pouget J. Visual control of locomotion in Parkinson's disease. Brain 1999; 122: 111-120.
40. Bonnet AM, Loria Y, Saint-Hilaire MH, Lhermitte F, Agid Y. Does long-term aggravation of Parkinson's disease result from nondopaminergic lesion? Neurology 1987; 37: 1539-1542.
41. Agid Y, Graybiel AM, Ruberg M, et al. The efficacy of levodopa treatment declines in the course of Parkinson's disease: do nondopaminergic lesions play a role? Adv Neurol 1990; 53: 83-100.
42. Weinrich M, Koch K, Garcia F, Angel RW. Axial versus distal motor impairment in Parkinson's disease. Neurology 1988; 38: 540-545.
43. Bloem BR, Beckley DJ, van Dijk JG, Zwinderman AH, Remler MP, Roos RA. Influence of dopaminergic medication on automatic postural responses and balance impairment in Parkinson's disease. Mov Disord 1996; 11: 509-521.
44. Braak H, Braak E. Pathoanatomy of Parkinson's disease. J Neurol 2000; 247(Suppl. 2): II3-II10.
45. Deuschl G, Elble R. Essential tremor - neurodegenerative or nondegenerative disease towards a working definition of ET. Mov Disord 2009; 24: 2033-2041.
46. Shill HA, Adler CH, Sabbagh MN, et al. Pathologic findings in prospectively ascertained essential tremor subjects. Neurology 2008; 70: 1452-1455.
47. Louis ED, Faust PL, Vonsattel JP, et al. Neuropathological changes in essential tremor: 33 cases compared with 21 controls. Brain 2007; 130: 3297-3307.
48. Markesbery WR, Jicha GA, Liu H, Schmitt FA. Lewy body pathology in normal elderly subjects. J Neuropathol Exp Neurol 2009; 68: 816-822.
49. Büttner T, Kuhn W, Patzold T, Przuntek H. l-Dopa improves colour vision in Parkinson's disease. J Neural Transm Park Dis Dement Sect 1994; 7: 13-19.
50. Hutton JT, Morris JL, Elias JW. Levodopa improves spatial contrast sensitivity in Parkinson's disease. Arch Neurol 1993; 50: 721-724.
51. Mestre DR, Blin O, van den Brand CL, Azulay JP, Serratrice G. Effects of l-DOPA on spatiotemporal contrast sensitivity in Parkinson's disease. Adv Neurol 1996; 69: 503-511.